183 related articles for article (PubMed ID: 23159614)
1. CCAAT/enhancer binding protein β deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis.
Rahman SM; Choudhury M; Janssen RC; Baquero KC; Miyazaki M; Friedman JE
Biochem Biophys Res Commun; 2013 Jan; 430(1):336-9. PubMed ID: 23159614
[TBL] [Abstract][Full Text] [Related]
2. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
[TBL] [Abstract][Full Text] [Related]
4. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
5. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein arginine methyltransferase 3 activity selectively impairs liver X receptor-driven transcription of hepatic lipogenic genes in vivo.
Nahon JE; Groeneveldt C; Geerling JJ; van Eck M; Hoekstra M
Br J Pharmacol; 2018 Aug; 175(15):3175-3183. PubMed ID: 29774529
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
Beyer TP; Schmidt RJ; Foxworthy P; Zhang Y; Dai J; Bensch WR; Kauffman RF; Gao H; Ryan TP; Jiang XC; Karathanasis SK; Eacho PI; Cao G
J Pharmacol Exp Ther; 2004 Jun; 309(3):861-8. PubMed ID: 14960661
[TBL] [Abstract][Full Text] [Related]
8. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.
Ide T; Shimano H; Yoshikawa T; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Nakakuki M; Yatoh S; Iizuka Y; Tomita S; Ohashi K; Takahashi A; Sone H; Gotoda T; Osuga J; Ishibashi S; Yamada N
Mol Endocrinol; 2003 Jul; 17(7):1255-67. PubMed ID: 12730332
[TBL] [Abstract][Full Text] [Related]
10. Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice.
van Straten EM; van Meer H; Huijkman NC; van Dijk TH; Baller JF; Verkade HJ; Kuipers F; Plösch T
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1171-8. PubMed ID: 19724022
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.
Grefhorst A; Elzinga BM; Voshol PJ; Plösch T; Kok T; Bloks VW; van der Sluijs FH; Havekes LM; Romijn JA; Verkade HJ; Kuipers F
J Biol Chem; 2002 Sep; 277(37):34182-90. PubMed ID: 12097330
[TBL] [Abstract][Full Text] [Related]
13. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR.
Cha JY; Repa JJ
J Biol Chem; 2007 Jan; 282(1):743-51. PubMed ID: 17107947
[TBL] [Abstract][Full Text] [Related]
14. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.
Jung UJ; Millman PN; Tall AR; Deckelbaum RJ
Biochim Biophys Acta; 2011 Sep; 1811(9):491-7. PubMed ID: 21704188
[TBL] [Abstract][Full Text] [Related]
15. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation.
Hijmans BS; Tiemann CA; Grefhorst A; Boesjes M; van Dijk TH; Tietge UJ; Kuipers F; van Riel NA; Groen AK; Oosterveer MH
FASEB J; 2015 Apr; 29(4):1153-64. PubMed ID: 25477282
[TBL] [Abstract][Full Text] [Related]
16. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells.
Murthy S; Born E; Mathur SN; Field FJ
J Lipid Res; 2002 Jul; 43(7):1054-64. PubMed ID: 12091489
[TBL] [Abstract][Full Text] [Related]
17. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
[TBL] [Abstract][Full Text] [Related]
18. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.
Miao B; Zondlo S; Gibbs S; Cromley D; Hosagrahara VP; Kirchgessner TG; Billheimer J; Mukherjee R
J Lipid Res; 2004 Aug; 45(8):1410-7. PubMed ID: 15145986
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
